AU2012368815B2 - A composition and use thereof in the treatment of anal rhagades - Google Patents
A composition and use thereof in the treatment of anal rhagades Download PDFInfo
- Publication number
- AU2012368815B2 AU2012368815B2 AU2012368815A AU2012368815A AU2012368815B2 AU 2012368815 B2 AU2012368815 B2 AU 2012368815B2 AU 2012368815 A AU2012368815 A AU 2012368815A AU 2012368815 A AU2012368815 A AU 2012368815A AU 2012368815 B2 AU2012368815 B2 AU 2012368815B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- hibiscus
- anal
- ranges
- beta glucan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 241000842539 Rhagades Species 0.000 title claims abstract description 58
- 206010040849 Skin fissures Diseases 0.000 title claims abstract description 58
- 238000011282 treatment Methods 0.000 title claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 29
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 27
- 235000005206 Hibiscus Nutrition 0.000 claims abstract description 27
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims abstract description 27
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims description 30
- 235000018102 proteins Nutrition 0.000 claims description 28
- 239000000499 gel Substances 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 240000001432 Calendula officinalis Species 0.000 claims description 6
- 235000013939 Malva Nutrition 0.000 claims description 6
- 235000000060 Malva neglecta Nutrition 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000000413 hydrolysate Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 235000019198 oils Nutrition 0.000 claims description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 5
- 229920000715 Mucilage Polymers 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 4
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 4
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 claims description 4
- 235000003880 Calendula Nutrition 0.000 claims description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 239000008168 almond oil Substances 0.000 claims description 4
- 235000021324 borage oil Nutrition 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 230000001804 emulsifying effect Effects 0.000 claims description 4
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229940075529 glyceryl stearate Drugs 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- 229940057874 phenyl trimethicone Drugs 0.000 claims description 4
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 claims description 4
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 3
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 240000004507 Abelmoschus esculentus Species 0.000 claims description 3
- 235000019489 Almond oil Nutrition 0.000 claims description 3
- 240000004355 Borago officinalis Species 0.000 claims description 3
- 235000007689 Borago officinalis Nutrition 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 229920006243 acrylic copolymer Polymers 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 229940056318 ceteth-20 Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 229940008099 dimethicone Drugs 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 235000011477 liquorice Nutrition 0.000 claims description 3
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 229940101267 panthenol Drugs 0.000 claims description 3
- 235000020957 pantothenol Nutrition 0.000 claims description 3
- 239000011619 pantothenol Substances 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 229940100459 steareth-20 Drugs 0.000 claims description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 235000003934 Abelmoschus esculentus Nutrition 0.000 claims description 2
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 235000017011 Mandorlo dulce Nutrition 0.000 claims description 2
- 244000076313 Mandorlo dulce Species 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003531 protein hydrolysate Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 229940048081 trisodium ethylenediamine disuccinate Drugs 0.000 claims description 2
- QEHXDDFROMGLSP-VDBFCSKJSA-K trisodium;(2s)-2-[2-[[(1s)-1-carboxy-2-carboxylatoethyl]amino]ethylamino]butanedioate Chemical compound [Na+].[Na+].[Na+].OC(=O)C[C@@H](C([O-])=O)NCCN[C@H](C([O-])=O)CC([O-])=O QEHXDDFROMGLSP-VDBFCSKJSA-K 0.000 claims description 2
- 241000218033 Hibiscus Species 0.000 claims 7
- 240000000982 Malva neglecta Species 0.000 claims 2
- 241001075721 Hibiscus trionum Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 32
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 15
- 210000005070 sphincter Anatomy 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000002255 anal canal Anatomy 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000000981 epithelium Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 210000005072 internal anal sphincter Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000382417 Malva Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 208000034347 Faecal incontinence Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007464 sphincterotomy Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000009723 vascular congestion Effects 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 2
- 231100000938 Guinea Pig Maximization Test Toxicity 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036983 biotransformation Effects 0.000 description 2
- -1 carboxymethyl betaglucan Chemical compound 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010058442 Hypertrophic anal papilla Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010044038 Tooth erosion Diseases 0.000 description 1
- 101710182532 Toxin a Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000007433 macroscopic evaluation Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000010309 melting process Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2012/000027 WO2013114410A1 (en) | 2012-01-30 | 2012-01-30 | A composition and use thereof in the treatment of anal rhagades |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012368815A1 AU2012368815A1 (en) | 2014-09-18 |
| AU2012368815B2 true AU2012368815B2 (en) | 2018-03-01 |
Family
ID=46001672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012368815A Active AU2012368815B2 (en) | 2012-01-30 | 2012-01-30 | A composition and use thereof in the treatment of anal rhagades |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9345747B2 (es) |
| EP (1) | EP2646039B1 (es) |
| JP (1) | JP5903505B2 (es) |
| KR (1) | KR101599447B1 (es) |
| CN (2) | CN104114177A (es) |
| AU (1) | AU2012368815B2 (es) |
| BR (1) | BR112014018850A8 (es) |
| CA (1) | CA2863369C (es) |
| DK (1) | DK2646039T3 (es) |
| ES (1) | ES2485490T3 (es) |
| HK (1) | HK1186378A1 (es) |
| HR (1) | HRP20140594T1 (es) |
| IL (1) | IL233875A (es) |
| IN (1) | IN2014MN01733A (es) |
| MX (1) | MX336204B (es) |
| PL (1) | PL2646039T3 (es) |
| RS (1) | RS53457B (es) |
| RU (1) | RU2580622C2 (es) |
| SA (1) | SA113340239B1 (es) |
| SG (1) | SG11201404413UA (es) |
| SI (1) | SI2646039T1 (es) |
| TW (1) | TWI495476B (es) |
| WO (1) | WO2013114410A1 (es) |
| ZA (1) | ZA201405208B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105848730B (zh) | 2013-12-24 | 2019-12-13 | 宝洁公司 | 提供增强的护肤活性物质渗透的化妆品组合物和方法 |
| ITRM20150163A1 (it) * | 2015-04-17 | 2016-10-17 | Uniderm Farm S R L | Composizioni farmaceutiche per il trattamento delle ragadi anali |
| US10117826B2 (en) | 2016-03-31 | 2018-11-06 | Peter Angia Pham | Bodily lubricating and moisturizing compositions containing plant mucilage |
| US10835504B2 (en) | 2018-04-18 | 2020-11-17 | G&S Laboratories, Inc. | Compositions to treat anal itch |
| WO2020022991A2 (en) * | 2018-05-02 | 2020-01-30 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | Topical compositions for stretch marks on the skin |
| RU2771015C2 (ru) * | 2020-09-25 | 2022-04-25 | Общество с ограниченной ответственностью "ФАРМКОММ" | Фармацевтическая композиция в виде мази для лечения геморроя |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004163A1 (en) * | 1992-08-21 | 1994-03-03 | Alpha-Beta Technology, Inc. | Novel glucan preparation |
| WO1998046205A1 (fr) * | 1997-04-16 | 1998-10-22 | Laboratoires Serobiologiques (Societe Anonyme) | Utilisation d'une fraction proteique extraite de graines d'hibiscus esculentus en cosmetique |
| JP2004051533A (ja) * | 2002-07-19 | 2004-02-19 | Ichimaru Pharcos Co Ltd | ヒアルロン酸合成促進剤 |
| US6956120B2 (en) * | 2000-11-09 | 2005-10-18 | Yasushi Onaka | β-1.3-1.6 glucan (Aureobasidium medium) |
| US20060093657A1 (en) * | 2004-11-04 | 2006-05-04 | Biofarmitalia S.P.A. | Patch containing a substance selected from tars having reducing characteristics in dermatology |
| DE202007004856U1 (de) * | 2007-04-01 | 2007-06-06 | Rühle, Wilfried, Dipl.-Ing. | CHM Anti Aging Komplex |
| US20090202664A1 (en) * | 2008-02-11 | 2009-08-13 | Svetislav Mikalacki | Herbal cream or oil for the treatment hemorroids and wounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379719B1 (en) * | 1998-04-08 | 2002-04-30 | Laboratories Serobiologiques (Societe Anonyme) | Use of at least one protein fraction extracted from Hibiscus esculentus seeds and cosmetic composition containing such a fraction |
| CN1233469A (zh) * | 1998-04-28 | 1999-11-03 | 王京杭 | 组织修复促进剂 |
| JP2002204687A (ja) * | 2000-11-09 | 2002-07-23 | Onaka Yasushi | β−１．３−１．６グルカン（アウレオバシジウム培養液）の医療、保健、福祉、食品および各種産業分野での応用 |
| JP2003104832A (ja) * | 2001-09-28 | 2003-04-09 | Chifure Keshohin:Kk | 皮膚外用剤 |
| PL1622627T3 (pl) * | 2003-05-02 | 2013-11-29 | Ceapro Inc | Kompozycje farmaceutyczne zawierające zbożowy BETA(1-3)BETA(1-4)-glukan |
| RU2277920C2 (ru) * | 2004-02-24 | 2006-06-20 | Государственное Учреждение "Пятигорский Государственный Научно-Исследовательский Институт Курортологии Министерства Здравоохранения Российской Федерации" | Способ лечения детей, больных хроническим вирусным гепатитом, с применением сульфидных ванн и слабоуглекислой минеральной водой |
| JP5048935B2 (ja) * | 2005-08-24 | 2012-10-17 | 株式会社ヤクルト本社 | 保湿剤 |
| CN101095482B (zh) * | 2007-07-05 | 2012-02-15 | 中国科学院长春应用化学研究所 | 制备膳食纤维食品用大麦麦麸或燕麦麦麸的制法 |
| ITUD20100112A1 (it) * | 2010-06-09 | 2011-12-10 | Farma Derma S R L | Preparazione per uso vaginale e rettale e relativo procedimento di produzione |
| CN102084963A (zh) * | 2010-09-29 | 2011-06-08 | 吉林省农业机械研究院 | 一种制备燕麦麦麸膳食纤维食品的方法 |
-
2012
- 2012-01-30 AU AU2012368815A patent/AU2012368815B2/en active Active
- 2012-01-30 CN CN201280068454.1A patent/CN104114177A/zh active Pending
- 2012-01-30 CA CA2863369A patent/CA2863369C/en active Active
- 2012-01-30 SI SI201230046T patent/SI2646039T1/sl unknown
- 2012-01-30 IN IN1733MUN2014 patent/IN2014MN01733A/en unknown
- 2012-01-30 BR BR112014018850A patent/BR112014018850A8/pt not_active IP Right Cessation
- 2012-01-30 JP JP2014553861A patent/JP5903505B2/ja active Active
- 2012-01-30 RU RU2014129391/15A patent/RU2580622C2/ru not_active IP Right Cessation
- 2012-01-30 MX MX2014009244A patent/MX336204B/es unknown
- 2012-01-30 SG SG11201404413UA patent/SG11201404413UA/en unknown
- 2012-01-30 EP EP12716670.0A patent/EP2646039B1/en active Active
- 2012-01-30 US US14/359,504 patent/US9345747B2/en active Active
- 2012-01-30 WO PCT/IT2012/000027 patent/WO2013114410A1/en active Application Filing
- 2012-01-30 KR KR1020147024430A patent/KR101599447B1/ko not_active IP Right Cessation
- 2012-01-30 ES ES12716670.0T patent/ES2485490T3/es active Active
- 2012-01-30 DK DK12716670.0T patent/DK2646039T3/da active
- 2012-01-30 PL PL12716670T patent/PL2646039T3/pl unknown
- 2012-01-30 CN CN201910159524.8A patent/CN109865000A/zh active Pending
- 2012-01-30 RS RS20140405A patent/RS53457B/en unknown
-
2013
- 2013-01-25 TW TW102102852A patent/TWI495476B/zh not_active IP Right Cessation
- 2013-01-27 SA SA113340239A patent/SA113340239B1/ar unknown
- 2013-12-10 HK HK13113705.4A patent/HK1186378A1/xx not_active IP Right Cessation
-
2014
- 2014-06-26 HR HRP20140594AT patent/HRP20140594T1/hr unknown
- 2014-07-16 ZA ZA2014/05208A patent/ZA201405208B/en unknown
- 2014-07-30 IL IL233875A patent/IL233875A/en active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994004163A1 (en) * | 1992-08-21 | 1994-03-03 | Alpha-Beta Technology, Inc. | Novel glucan preparation |
| WO1998046205A1 (fr) * | 1997-04-16 | 1998-10-22 | Laboratoires Serobiologiques (Societe Anonyme) | Utilisation d'une fraction proteique extraite de graines d'hibiscus esculentus en cosmetique |
| US6956120B2 (en) * | 2000-11-09 | 2005-10-18 | Yasushi Onaka | β-1.3-1.6 glucan (Aureobasidium medium) |
| JP2004051533A (ja) * | 2002-07-19 | 2004-02-19 | Ichimaru Pharcos Co Ltd | ヒアルロン酸合成促進剤 |
| US20060093657A1 (en) * | 2004-11-04 | 2006-05-04 | Biofarmitalia S.P.A. | Patch containing a substance selected from tars having reducing characteristics in dermatology |
| DE202007004856U1 (de) * | 2007-04-01 | 2007-06-06 | Rühle, Wilfried, Dipl.-Ing. | CHM Anti Aging Komplex |
| US20090202664A1 (en) * | 2008-02-11 | 2009-08-13 | Svetislav Mikalacki | Herbal cream or oil for the treatment hemorroids and wounds |
Non-Patent Citations (1)
| Title |
|---|
| BRYANT L A ET AL, JOURNAL OF FOOD SCIENCE, (19880101), vol. 53, no. 3, pages 810 - 816 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012368815B2 (en) | A composition and use thereof in the treatment of anal rhagades | |
| KR20030009454A (ko) | 진세노사이드Ｒｂ1으로 된 피부조직 재생촉진제 | |
| EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
| KR20120118064A (ko) | 염증후 과다색소침착의 감소로 비코카서스인 모집단에서의 여드름 치료를 위한 아다팔렌과 벤조일 퍼옥사이드의 조합물을 포함하는 피부용 조성물 | |
| BR112021003877A2 (pt) | composições farmacêuticas à base de óleo semissólidas que contêm pirfenidona para aplicação em reparo tecidual | |
| JP6121561B2 (ja) | 組織再生のための組成物および方法 | |
| CN103347507A (zh) | 用于治疗痤疮的褪黑激素以及抗微生物剂或抗菌剂 | |
| WO2004100923A1 (fr) | Composition a usage externe administree par voie percutanee | |
| US10426803B2 (en) | Topical medicament for skin and mucosal injuries | |
| US11696907B2 (en) | Wound healing composition | |
| EP3087993B1 (en) | Pharmaceutical composition comprising acetyl hexapeptide-8 and pentapeptide-18 for treating anal fissures | |
| US20020176876A1 (en) | Topical therapeutic skin care system | |
| US7780992B2 (en) | Antiviral medicament | |
| US20150306221A1 (en) | Mixture of Betamethasone and Tranilast with a Transdermal Gel for Scar Treatment | |
| CN114306107A (zh) | 功效型皮肤用产品及其制备方法 | |
| KR100892742B1 (ko) | 여드름 치료용 피부 외용제 조성물 | |
| JP2016033137A (ja) | 裂肛の治療における組成物及びその使用 | |
| EP3081212A1 (en) | Carboxymethylcysteine for topical treatment of stretch marks | |
| WO2024073013A1 (en) | Combination treatment of dermal and transdermal fibrotic diseases, disorders and associated pain and inflammation | |
| US20090111783A1 (en) | Dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin for treating the hyperpigmentation of pathological scars |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |